Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-ND5 pseudogene 31 is a segment of nuclear DNA that originated from the mitochondrial ND5 gene through a process where mitochondrial DNA fragments are incorporated into the nuclear genome (sometimes called "NUMTs"—nuclear mitochondrial DNA segments). Unlike the original ND5 gene encoded by mitochondrial DNA, MTND5P31 does not produce a functional protein. As a pseudogene, it cannot complement or substitute for defects in the mitochondrial ND5 gene and plays no known biological or disease role. It is not considered a therapeutic target, does not interact with drugs, and is not used as a biomarker. Its identification is important mainly for genomic studies and to ensure that functional studies of ND5 do not accidentally analyze this noncoding pseudogene instead of the true mitochondrial gene[2][6][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-ND5 pseudogene 31 (MTND5P31).